-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161

Benzinga·07/15/2026 11:46:09
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $160 to $161.